Raras
Buscar doenças, sintomas, genes...
Neurofibromatose tipo 1 por mutação ou deleção intragênica em NF1
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

O algoritmo de Shapiro—Senapathy (S&S) é um método computacional para identificar sítios de *splicing* em genes eucarióticos. O algoritmo emprega uma fórmula de pontuação de Matriz de Ponderação Posicional (PWM) para prever sítios de *splicing* doador e aceptor em um dado gene. Essa metodologia tem sido utilizada para descobrir sítios de *splicing* e mutações em sítios de *splicing* causadoras de doenças no genoma humano, e tornou-se uma ferramenta padrão em genômica clínica.

🏥
SUS: Cobertura mínimaScore: 15%
1 medicamentos CEAFCID-10: Q85.0
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (5)
0202010503
Cariótipo — bandas G, Q ou Rgenetic_test
0202010600
Pesquisa de microdeleções/microduplicações por FISHlab_test
0202010694
Sequenciamento completo do exoma (WES)rehabilitation
0202010260
Dosagem de alfa-fetoproteína
0301070040
Atendimento em reabilitação — doenças raras
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
12 sintomas
🦴
Ossos e articulações
11 sintomas
😀
Face
10 sintomas
❤️
Coração
6 sintomas
🫘
Rins
3 sintomas
👂
Ouvidos
2 sintomas

+ 25 sintomas em outras categorias

Características mais comuns

90%prev.
Mancha café com leite
Muito frequente (99-80%)
90%prev.
Hipertelorismo
Muito frequente (99-80%)
55%prev.
Mãos grandes
Frequente (79-30%)
55%prev.
Traços faciais grosseiros
Frequente (79-30%)
55%prev.
Sardas inguinais
Frequente (79-30%)
55%prev.
Pé longo
Frequente (79-30%)
71sintomas
Muito frequente (2)
Frequente (22)
Ocasional (26)
Muito raro (21)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 71 características clínicas mais associadas, ordenadas por frequência.

Mancha café com leiteCafe-au-lait spot
Muito frequente (99-80%)90%
HipertelorismoHypertelorism
Muito frequente (99-80%)90%
Mãos grandesLarge hands
Frequente (79-30%)55%
Traços faciais grosseirosCoarse facial features
Frequente (79-30%)55%
Sardas inguinaisInguinal freckling
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Últimos 10 anos200publicações
Pico2025151 papers
Linha do tempo
2026Hoje · 2026📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição.

Autosomal dominant
NF1NeurofibrominDisease-causing germline mutation(s) (loss of function) inAltamente restrito
FUNÇÃO

Stimulates the GTPase activity of Ras. NF1 shows greater affinity for Ras GAP, but lower specific activity. May be a regulator of Ras activity

LOCALIZAÇÃO

NucleusNucleus, nucleolusCell membrane

VIAS BIOLÓGICAS (1)
RAS signaling downstream of NF1 loss-of-function variants
MECANISMO DE DOENÇA

Neurofibromatosis 1

A disease characterized by patches of skin pigmentation (cafe-au-lait spots), Lisch nodules of the iris, tumors in the peripheral nervous system and fibromatous skin tumors. Individuals with the disorder have increased susceptibility to the development of benign and malignant tumors.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
17.9 TPM
Cérebro - Hemisfério cerebelar
17.1 TPM
Cerebelo
15.3 TPM
Nervo tibial
14.9 TPM
Tireoide
14.1 TPM
OUTRAS DOENÇAS (12)
neurofibromatosis, familial spinalneurofibromatosis type 1juvenile myelomonocytic leukemiaWatson syndrome
HGNC:7765UniProt:P21359

Medicamentos aprovados (FDA)

2 medicamentos encontrados nos registros da FDA americana.

💊 Gomekli (MIRDAMETINIB)
💊 KOSELUGO (SELUMETINIB)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

7,190 variantes patogênicas registradas no ClinVar.

🧬 NF1: NM_001042492.3(NF1):c.1932del (p.Met645fs) ()
🧬 NF1: NM_001042492.3(NF1):c.388C>A (p.His130Asn) ()
🧬 NF1: NM_001042492.3(NF1):c.1541dup (p.Pro516fs) ()
🧬 NF1: NM_001042492.3(NF1):c.5533A>G (p.Ile1845Val) ()
🧬 NF1: NM_001042492.3(NF1):c.2895A>G (p.Ile965Met) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 4 variantes classificadas pelo ClinVar.

3
1
Patogênica (75.0%)
Benigna (25.0%)
VARIANTES MAIS SIGNIFICATIVAS
NF1: NM_001042492.3(NF1):c.1155del (p.Arg385_Ile386insTer) [Likely pathogenic]
NF1: NM_001042492.3(NF1):c.3974G>C (p.Arg1325Thr) [Pathogenic/Likely pathogenic]
NF1: NM_001042492.3(NF1):c.1523T>C (p.Leu508Pro) [Pathogenic/Likely pathogenic]
NF1: NM_001042492.3(NF1):c.1137C>T (p.Cys379=) [Benign/Likely benign]

Vias biológicas (Reactome)

2 vias biológicas associadas aos genes desta condição.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Neurofibromatose tipo 1 por mutação ou deleção intragênica em NF1

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

Familial medullary thyroid carcinoma secondary to an SLC30A9 intragenic deletion and translation reinitiation.

medRxiv : the preprint server for health sciences2026 Feb 27

While most individuals with familial medullary thyroid carcinoma (fMTC) carry RET mutations, in some instances the causative mutations remain unknown. We studied two related families with RET -negative fMTC in 21 affected individuals through linkage analysis, exome/genome sequencing, and high-density array comparative genomic hybridization. We identified a novel heterozygous 40kb intragenic SLC30A9 deletion which segregated with the disease in all affected individuals. The mutant transcript escaped nonsense-mediated decay and resulted in the production of N-terminally truncated proteins via translation reinitiation from in-frame AUG codons located downstream of the deletion. These proteins showed increased stability and their expression in an MTC cell line increased cell proliferation and clonogenic capacity, supporting an oncogenic role. These findings expand the genetic background of fMTC beyond RET mutations and implicate translation reinitiation in the etiology of cancer susceptibility syndromes secondary to structural genomic variants.

#2

IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma.

Blood2026 Mar 13

Lenalidomide, a maintenance treatment in multiple myeloma first-line therapy, increases the risk of secondary malignancies, including B-cell precursor acute lymphoblastic leukemia (B‑ALL). We present a comprehensive molecular characterization of 57 patients with lenalidomide-associated B-ALL (LenB-ALL), revealing three mutational subgroups: (1) TP53mt (30%), (2) IDH2mt (p.R140Q) (23%) and (3) other, including NRAS/KRASmt. Remarkably, IDH2 R140Q mutations were highly enriched in LenB-ALL compared to primary B-ALL (p<0.001). Furthermore, IKZF1 intragenic deletions - often subclonal and likely RAG-mediated - were observed in 54% (7/13) of IDH2mt LenB-ALL cases. IDH2 mutations were not restricted to the leukemic clone: they persisted during MRD-negative remission and were identified in lymphoid as well as myeloid cell populations using fluorescence-activated cell sorting and single-cell RNA sequencing. This indicates a preleukemic origin of the IDH2 mutation within the context of clonal hematopoiesis. Transcriptomic and DNA methylation analyses revealed a distinct gene expression profile and a DNA hypermethylation phenotype in IDH2mt LenB-ALL, including IDH2mt-specific as well as lenalidomide-associated features. We propose that lenalidomide promotes expansion of IDH2-mutated clonal hematopoiesis and, via IKAROS downregulation, induces a maturation arrest at the B-cell precursor stage. Subsequent genetic or epigenetic alterations render leukemogenesis independent of ongoing lenalidomide exposure. Altogether, these data define IDH2mt B-ALL as a distinct molecular subtype that is markedly overrepresented after lenalidomide treatment and highlight clonal hematopoiesis as a key contributing factor in the development of LenB-ALL.

#3

Alanine-scanning mutagenesis library of MreB reveals distinct roles for regulating cell shape and viability.

PLoS genetics2026 Mar

The bacterial actin-homolog MreB is a crucial component of the Rod-system (elongasome) that maintains rod shape in many bacteria. It is localized beneath the cytoplasmic membrane, where it organizes the elongasome complex. Depletion or deletion of mreB results in loss of rod shape and cell death; however, the mechanism of how MreB operates is not known. Past studies have reported that mutations in mreB cause varying degrees of cell shape and size alterations based on the type and position of the substitution. To better understand the role of MreB in rod shape formation we have taken the first truly systematic approach by replacing the native copy of mreB with an alanine-scanning mutagenesis library. Surprisingly, we observed stably growing spherical mutants that have lost MreB's function(s) for shape regulation without losing viability. Hence, MreB has vital functions related to growth in addition to shape maintenance that can be separated. In support of this, rod shape suppressor analysis of these spherical mutants only revealed reversions or intragenic mreB mutations, suggesting that MreB is indispensable for rod shape. Additionally, our results imply the elongasome is no longer active in these strains, suggesting a novel way for rod shaped bacteria to synthesize cell wall.

#4

Metabolic and behavioral effects of neurofibromin result from differential recruitment of MAPK and mTOR signaling.

PLoS genetics2026 Mar

Neurofibromatosis type 1 results from mutations in the NF1 gene and its encoded neurofibromin protein. This condition produces multiple symptoms, including tumors, behavioral alterations, and metabolic changes. Molecularly, neurofibromin mutations affect Ras activity, influencing multiple downstream signaling pathways, including MAPK (Raf/MEK/ERK) and PI3K/Akt/mTOR signaling. This pleiotropy raises the question of which pathways could be targeted to treat the disease symptoms, and whether different phenotypes driven by neurofibromin mutations exhibit similar or diverging dependence on the signaling pathways downstream of Ras. To test this, we examined metabolic and behavioral alterations in the genetically tractable Drosophila neurofibromatosis type 1 model. In vivo genetic analysis revealed that behavioral effects of neurofibromin were mediated by MEK signaling, with no necessity for Akt. In contrast, metabolic effects of neurofibromin were mediated by coordinated actions MEK/ERK and Akt/mTOR/S6K/4E-BP signaling. At the systemic level, loss of neurofibromin dysregulated metabolism via molecular effects in interneurons and muscle. These changes were accompanied by altered muscle mitochondria morphology, with no concomitant changes in neuronal ultrastructure or neuronal mitochondria. Overall, this suggests that neurofibromin mutations affect multiple signaling cascades downstream of Ras, which differentially affect metabolic and behavioral neurofibromatosis type 1 phenotypes.

#5

Neurofibromin 1 (NF1) Splicing Mutation c.61-2A>G: From Aberrant mRNA Processing to Therapeutic Implications In Silico.

International journal of molecular sciences2026 Jan 23

The neurofibromin 1 (NF1) splice-site mutation c.61-2A>G (rs1131691100) is a rare, pathogenic, autosomal dominant variant that disrupts NF1 tumor-suppressor function, causing neurofibromatosis type 1 (NF1). Its pathogenic mechanism is poorly understood, and the potential for personalized therapeutic genome editing remains unknown due to the absence of a standard framework for investigating splicing disorders. Here, we performed a comprehensive multi-omics analysis of a de novo c.61-2A>G case from South Korea, integrating short- and long-read whole genome sequencing, whole transcriptome sequencing, and methylation profiling. We confirm that c.61-2A>G abolishes the canonical splice acceptor site, activating a cryptic splice acceptor 16 nucleotides downstream in exon 2. This splicing shift generates a 16-nucleotide deletion, causing a frameshift and premature stop codon that truncates the protein's N-terminal region. Long-read sequencing further reveals that the mutation creates a novel CpG dinucleotide, which is methylated in the majority of reads. Finally, we assessed therapeutic correction strategies, revealing that CRISPR-Cas9 prime editing is the only viable approach for in vivo correction. This study provides the first comprehensive multi-omics characterization of the NF1 c.61-2A>G mutation and establishes a minimal framework for precision therapeutic development in silico in monogenic splicing disorders.

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 197

2026

Familial medullary thyroid carcinoma secondary to an SLC30A9 intragenic deletion and translation reinitiation.

medRxiv : the preprint server for health sciences
2026

Case Report: Somatic NF2 mutation in a vestibular schwannoma arising in a patient with neurofibromatosis type 1.

Frontiers in oncology
2026

IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma.

Blood
2026

Alanine-scanning mutagenesis library of MreB reveals distinct roles for regulating cell shape and viability.

PLoS genetics
2026

Excessive intraoperative hemorrhage during orthognathic surgery in a patient with neurofibromatosis type 1: a case report and literature review.

Oral and maxillofacial surgery
2026

Precision restoration of complex cervical instability and decompression for neurofibromatosis type I: a case report using patient-specific 3D-printed templates.

Frontiers in surgery
2026

Isolated Anterior Mesenteric Neurofibroma: A Rare Manifestation of Neurofibromatosis Type 1.

Cureus
2026

Metabolic and behavioral effects of neurofibromin result from differential recruitment of MAPK and mTOR signaling.

PLoS genetics
2026

Ossification of Mandibular Central Giant Cell Granuloma (CGCG) in Neurofibromatosis Type 1 Patients.

Cancer diagnosis &amp; prognosis
2026

Duodenal ampullary neuroendocrine tumor, high risk gastrointestinal stromal tumor, and gastric leiomyoma in a patient with neurofibromatosis type 1: a rare case report and literature review.

Frontiers in oncology
2026

Unusual Presentation of Plexiform Neurofibroma Embedded with Large Comedones: A Case Report.

Case reports in dermatology
2026

Bilateral juvenile-onset cataracts associated with GCNT2 variants.

Ophthalmic genetics
2026

High-Yield DNA-Based Neurofibromatosis Type 1 Diagnostics Reveal Population-Specific Mutation Landscape in 1917 Koreans.

The Journal of molecular diagnostics : JMD
2026

Case report of breastfeeding after maternal iodine contrast: neonatal hypothyroidism revealing an underlying congenital disorder.

International breastfeeding journal
2026

Neurofibromin 1 (NF1) Splicing Mutation c.61-2A>G: From Aberrant mRNA Processing to Therapeutic Implications In Silico.

International journal of molecular sciences
2026

AlphaGenome-enabled analysis of non-coding regulatory variants underlying RHD expression with wet-lab validation.

bioRxiv : the preprint server for biology
2025

Laryngeal neurofibroma: case report and review of the literature.

Frontiers in oncology
2026

A Large Deletion With a Large Impact: Homozygous 5,600 bp Deletion of the GALNT3 Gene Causing Hyperphosphatemic Tumoral Calcinosis.

Kidney medicine
2026

Diagnostic yield of genome sequencing in children with progressive movement disorders.

Brain : a journal of neurology
2026

Altered Neuronal Architecture in Induced Pluripotent Stem Cells-Derived Neurons from Patients with Schizophrenia Harboring CNTNAP2 Deletion.

Stem cells and development
2026

Mutations and structural variants arising during double-strand break repair.

Proceedings of the National Academy of Sciences of the United States of America
2025

Internal carotid artery sympathetic plexus neurofibroma - A case report.

Surgical neurology international
2026

[Clinical characteristics and genetic analysis of 22 Chinese pedigrees affected with Neurofibromatosis type I].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2025

Caffeine May Delay the Radiation-Induced Nucleoshuttling of the ATM Kinase and Reduce the Recognition of the DNA Double-Strand Breaks in Human Cells.

Biomolecules
2026

Metachronous Pheochromocytoma and Cholangiocarcinoma in a patient with Neurofibromatosis type 1: a case report.

Oxford medical case reports
2026

Inhibition of Cxcr4 chemokine receptor signaling improves habituation learning in a zebrafish model of neurofibromatosis.

Disease models &amp; mechanisms
2026

Novel mega-deletion in BFSP1 causing autosomal recessive juvenile cataract in a Pakistani consanguineous family.

Molecular biology reports
2026

Pharmacokinetic recall study of Estonian Biobank participants with novel genetic variants in CYP2C19 and CYP2D6.

NPJ genomic medicine
2026

Asthma-mediated control of optic glioma growth via T cell-microglia interactions: A mathematical model.

NPJ systems biology and applications
2026

Unraveling cardiac anomalies in pediatric neurofibromatosis type 1: insights and implications.

European journal of pediatrics
2026

Neurofibromatosis Type 1 in Ecuador: genotype-phenotype correlations from a case series.

Medwave
2026

NF1 with Multiple Cardiac Structural Abnormalities Leading to Cerebral Infarction.

Diagnostics (Basel, Switzerland)
2025

Bilateral frontal periventricular nodular heterotopia: a distinctive cortical malformation.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
2025

RUNX1-FPDMM in families with mild thrombocytopenia and platelet function anomalies: a case series.

Frontiers in medicine
2026

Concurrent Juvenile Myelomonocytic Leukemia and Gliomas in Patients With Neurofibromatosis Type 1.

Pediatric blood &amp; cancer
2025

Genetic activation of ERK2 recapitulates core neurodevelopmental features of Rasopathy syndromes in mice.

bioRxiv : the preprint server for biology
2025

From mutation to symptoms: a multi-center study on HNF1B-related nephropathy in Chinese children.

BMC nephrology
2025

A RUNX2 GFP reporter is expressed prior to osteochondral differentiation and models Metaphyseal Dysplasia with Maxillary Hypoplasia and Brachydactyly (MDMHB).

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2025

LEF1 intragenic deletions: is Wnt'er coming for T-ALL?

Blood
2026

Phenotypic characterization of neurofibromatosis type 1 in a large Chinese cohort: A cross-sectional study.

JAAD international
2025

Protein domain-specific genotype-phenotype correlation study of neurofibromatosis type 1.

Scientific reports
2025

Pharmacological inhibition of RAS pathway alleviates spine deformity in a mouse model of neurofibromatosis type 1.

Bone research
2025

Genetics and pathophysiology of Duchenne muscular dystrophy.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
2025

Neurofibromatosis Type 1: Genetic Mechanisms and Advances in Therapeutic Innovation.

Cancers
2025

Challenges and Progress for Treatment of Malignant Peripheral Nerve Sheath Tumors in the Context of Recent Successes for Sarcoma Therapy.

Cancers
2025

The Complete Plastome of 'Mejhoul' Date Palm: Genomic Markers and Varietal Identification.

International journal of molecular sciences
2025

Genetic characterization of a Chinese cohort of suspected pediatric NF1 patients: a large-scale study using optimized whole-exome sequencing.

Journal of human genetics
2025

Further evidence for a wide phenotypic and mutational spectrum of Cohen syndrome: case report and literature review.

Journal of applied genetics
2025

Exploring Optic Glioma and Type 1 Neurofibromatosis: A Literature Review of Case Reports.

Neuro-ophthalmology (Aeolus Press)
2025

Coexistence of ulcerative colitis and neurofibromatosis type 1: a case report and literature review.

Frontiers in medicine
2025

Bibliometric Analysis of Global Research on Cafe-Au-Lait Macules from 2000 to 2025: Development, Collaboration Patterns, and Emerging Trends.

Clinical, cosmetic and investigational dermatology
2026

Intragenic loss-of-function variants in transcription factors MAZ, FOXP1 and SIN3B in colobomatous microphthalmia.

Journal of medical genetics
2025

High Allelic Heterogeneity in Kazakhstani Patients with Neurofibromatosis Type 1: Results from the First Molecular Study.

Genes
2026

Infantile-Onset Ascending Hereditary Spastic Paraplegia due to a Homozygous ALS2 Exons 24-25 Deletion: Expanding the Genotypic Spectrum.

American journal of medical genetics. Part A
2026

Preimplantation genetic testing for neurofibromatosis type 1: molecular genetic aspects and impact on reproductive counseling.

Human reproduction (Oxford, England)
2025

[Identification of two novel NF1 mutations and genotype-phenotype analysis in patients with neurofibromatosis type 1].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
2026

In Vitro Mouse Lymphoma Cell (L5178Y Tk+/- 3.7.2C) Forward Mutation Assay.

Methods in molecular biology (Clifton, N.J.)
2025

A novel multion in a Chinese family with neurofibromatosis type 1: A case report.

Medicine
2025

Ataluren-Induced Functional Restoration of Neurofibromin in Fibroblasts From Neurofibromatosis Type 1 Patients With Nonsense Mutations.

MedComm
2025

A novel germline NF1 splicing variant drives the onset of an anorectal mucosal melanoma in a patient with a stable and durable nivolumab response.

Pathologica
2026

Malignant peripheral nerve sheath tumors in schwannomatosis: systematic review and meta-analysis.

Journal of neurosurgery
2026

Malignant peripheral nerve sheath tumors in schwannomatosis: a case series.

Journal of neurosurgery
2025

Comparative Analysis of Targeted RNA-Seq and Optical Genome Mapping for Detecting Gene Rearrangements in Acute Leukemia.

Cancers
2025

Clinical and molecular characterization of 148 pediatric neurofibromatosis type 1 patients: a single-center study identifying 14 novel variants.

European journal of pediatrics
2025

Pathogenic Neurofibromatosis type 1 gene variants in tumors of non-NF1 patients and role of R1276.

FEBS open bio
2025

Subtype distribution, clinical presentation, and molecular spectrum of neurofibromatosis type 1-associated breast cancer.

Breast (Edinburgh, Scotland)
2025

Enhanced detection and characterization of germline structural variants in cancer predisposition genes via genome sequencing.

Genetics in medicine open
2026

Malignant Phyllodes Tumor of the Breast in a Young Adult With Neurofibromatosis Type 1.

American journal of medical genetics. Part A
2025

Occipital Bone Defect With Meningoencephalocele and Plexiform Neurofibroma in Neurofibromatosis-1.

Cureus
2025

Case Report: Trametinib in the treatment of patients with metastatic lung adenocarcinoma harboring NF1 mutation: a case series and literature review.

Frontiers in oncology
2025

A Case Report: Co-Occurrence of TNRC6B Gene Variant and Xq28 Microdeletion Syndrome With Comprehensive Literature Review.

Birth defects research
2025

Cutaneous Neufibroma in the Absence of Classical NF1 Features: A Case Report and Literature Review.

Dermatopathology (Basel, Switzerland)
2025

Intragenic TTN Deletions in a Single Family with Dilated Cardiomyopathy.

The application of clinical genetics
2025

"To have children or not?" Between desire, responsibility, luck, and guilt: reproductive decision-making in individuals with neurofibromatosis type 1.

Orphanet journal of rare diseases
2025

Disruption of SPECC1L translation initiation by intragenic deletion: novel pathogenic mechanism in Teebi-hypertelorism syndrome.

NPJ genomic medicine
2025

Quadruple the Considerations: Four Genetic Conditions Unveiled in the Setting of Developmental Delays Including a Complex DMD Rearrangement, Telomere Biology Disorder, and Neurodevelopmental Disorders.

Journal of child neurology
2026

Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.

Molecular cancer therapeutics
2025

Juvenile xanthogranuloma as a potential early manifestation of neurofibromatosis type 1: A case report.

Medicine
2025

Current states in understanding oligodendroglia-mediated neurological issues in neurofibromatosis type 1 (NF1).

Acta neuropathologica communications
2025

Significance of incidental copy number variants in the Duchenne muscular dystrophy gene.

Neuromuscular disorders : NMD
2025

Defective but tumorigenic: the evolutionary and functional roles of mutated oncoviruses.

FEMS microbiology reviews
2025

An Autopsy Case of Neurofibromatosis Type 1 Mutation Detected in a Duodenal Lesion of Malignant Melanoma: A Case Report.

Cureus
2025

Therapeutic Advances in Neurofibromatosis Type 1: A Focus on Selumetinib.

Skin therapy letter
2025

A Novel 1259 bp Intragenic Deletion in the GJB2 Gene in a Mexican Family with Congenital Profound Hearing Loss.

Audiology research
2025

Progress in genetic mechanisms and precise treatment of neurocutaneous syndrome-related epilepsy.

Frontiers in neurology
2025

Heterozygous alterations of GTF2I at the Williams-Beuren syndrome's locus cause a neurodevelopmental disorder.

Journal of medical genetics
2025

Prospective characterization of germline variants in patients with gliomas and glioneuronal tumors.

Acta neuropathologica
2025

A Rare Case: Composite Paraganglioma-Ganglioneuroma in a Neurofibromatosis 1 Patient and Literature Review.

Neuro endocrinology letters
2025

Selumetinib Treatment in a Neurofibromatosis Type 1 Child With Second Hit Mutation on the NF1 Gene.

International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience
2025

RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.

Human genomics
2025

Moyamoya Syndrome, Epilepsy and Hydrocephalus in Neurofibromatosis Type 1.

International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience
2025

LEF1 intragenic deletion induces a dominant-negative isoform and unveils a Wnt/β-catenin vulnerability in T-ALL.

Blood
2025

Epigenetic Mechanisms in Neurofibromatosis Types 1 and 2.

Epigenomes
2025

A Loss-of-Function Variant Causing Primary Autosomal Recessive Hypertrophic Osteoarthropathy.

Cureus
2025

Colorectal cancer in a 13-year-old with constitutional mismatch repair deficiency and MUTYH heterozygosity.

JPGN reports
2025

Characterizing neurofibromin 1-altered breast cancer through genomic, functional, and clinical analyses.

Virchows Archiv : an international journal of pathology
2026

Integrated Genomic Approach: A Five Exon Intragenic Deletion in UNC80 Combines With a Novel Splice Variant to Cause IHPRF2 Syndrome in an Italian Family.

American journal of medical genetics. Part A
2026

Zebrafish neurofibromatosis type 1 mutants show disruption of sleep but not of circadian rhythms.

Sleep
2025

Serum miRNAs as biomarkers in Neurofibromatosis 1: New promising findings.

Journal of the neurological sciences
2025

Refined genotype-phenotype correlations in neurofibromatosis type 1 patients with NF1 point variants.

Journal of medical genetics
2025

Molecular Basis of Fracture Pseudarthrosis Associated with Neurofibromatosis Type 1.

Journal of the Pediatric Orthopaedic Society of North America
2025

Increased Prevalence of Psychiatric Disorders in Children with RASopathies: Comparing NF1, Noonan Syndrome Spectrum Disorder, and the General Population.

Genes
2025

Long-read sequencing for NF1 gene analysis: enhancing diagnostic accuracy for Neurofibromatosis type 1.

Human molecular genetics
2025

Speech and Language Disorders Associated With 7q31 Deletions Implicating FOXP2.

American journal of medical genetics. Part A
2025

Case Report: Phenotypic heterogeneity within an NF1 family: assessment of the pathogenicity of a de novo c.6640dupA shift mutation and a splice variant with an epilepsy phenotype.

Frontiers in neuroscience
2025

Spontaneous peripheral artery rupture in patients with neurofibromatosis type 1.

Journal of vascular surgery cases and innovative techniques
2025

Coupling chromosome organization to genome segregation in Archaea.

Nature communications
2025

A Fatal Case of Infection-Induced Neurofibromatosis Type 1 in an Adult.

Case reports in oncology
2026

Pigmented Birthmarks and Spinal Neurofibromas in KRAS Mosaicism-Not to Be Confused With NF1.

Pediatric dermatology
2025

New models for MPNST: establishment and comprehensive characterization of two tumor cell lines.

Cancer cell international
2025

Functional Analysis of Complex Structural and Splice-Altering Variants in the ARSB Gene Towards the Personalized Antisense-Based Therapy for Mucopolysaccharidosis Type VI Patients.

Human mutation
2025

β-Thalassemia Trait Caused by a SUPT5H Defect: First Report of an Intragenic Deletion.

Hemoglobin
2025

High-Throughput Targeted Drug Screening for NF1-associated High-Grade Gliomas with ATRX Deficiency.

bioRxiv : the preprint server for biology
2024

Utility of Genetic Testing of Various Tissues in Localized Mosaic Neurofibromatosis.

Acta dermatovenerologica Croatica : ADC
2025

Rare variants modulating phenotype in NF1 carriers.

Scientific reports
2025

An Isoform-Specific RUNX1C-BTG2 Axis Governs AML Quiescence and Chemoresistance.

Blood cancer discovery
2025

Malignant peripheral nerve sheath tumor in early childhood: a case report of a diagnostic challenge.

Frontiers in oncology
2025

Unraveling novel variants in the NF1 gene and investigating potential therapeutic strategies.

Scientific reports
2025

Effective treatment of non-fusion RET intragenic deletion lung adenocarcinoma with pralsetinib: a case report.

Frontiers in medicine
2025

A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.

The Journal of clinical investigation
2025

A transcriptomic, proteomic, and functional genetic atlas dissects neurofibromin function in the peripheral nervous system.

Proceedings of the National Academy of Sciences of the United States of America
2025

[A clinical case of type 1 neurofibromatosis associated with a rare genotype].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
2025

Phase Determination and Demonstration of Parental Mosaicism of Intragenic PRKN Deletions Initially Identified by Chromosomal Microarray Analysis.

Genes
2025

[Analysis of clinical characteristics and NF1 gene variants in a child with Neurofibroma-Noonan syndrome].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2025

Coexistence of Congenital Aniridia and Ptosis in a Patient with Neurofibromatosis Type I: A Case Report.

Case reports in ophthalmology
2025

Structural variation in nebulin and its impact on phenotype and inheritance: establishing a dominant distal phenotype caused by large deletions.

European journal of human genetics : EJHG
2025

Inhibition of Cxcr4 chemokine receptor signaling improves habituation learning and increases cAMP-PKA signaling in a zebrafish model of Neurofibromatosis type 1.

bioRxiv : the preprint server for biology
2025

Neurofibromatosis Type 1: Clinical and Imaging Perspectives From a Pediatric Case.

Case reports in radiology
2025

Ellis-Van Creveld Syndrome with Severe Mitral Valve Insufficiency Caused by a Homozygous Intragenic Deletion of the EVC Gene.

Molecular syndromology
2025

Rare Copy Number Variants Intersecting Parkinson's-associated Genes in a Cohort of children With Autism Spectrum Disorders.

Neuroscience insights
2025

Unraveling the molecular landscape of congenital pseudoarthrosis of the tibia: insights from a comprehensive analysis of 159 probands.

Orphanet journal of rare diseases
2025

Irritability in children with RASopathies, insights into emotional dysregulation and social impairment.

European child &amp; adolescent psychiatry
2025

Resolving the Diagnostic Odyssey in Inherited Retinal Dystrophies Through Long-Read Genome Sequencing.

American journal of medical genetics. Part A
2025

The Role of Artificial Intelligence in Identifying NF1 Gene Variants and Improving Diagnosis.

Genes
2025

Recent Advancement of Neurofibromatosis Type 1: A Narrative Review.

Acta neurologica Taiwanica
2025

Rapid Malignant Transformation of a Biopsy Proven Sporadic Soft Tissue Schwannoma to Spindle Cell MPNST With TP53 Mutation as an Early Event.

International journal of surgical pathology
2025

Clinical and epidemiological characterisation of neurofibromatosis type 1: Combined analysis of a reference hospital in Brazil and DataSUS.

Genetics and molecular biology
2025

Genome sequencing reveals CCDC88A variants in malformations of cortical development and immune dysfunction.

Human molecular genetics
2025

Increased insulin-like growth factor-1 concentrations in paediatric suprasellar low-grade glioma: an international multicentre study.

European journal of endocrinology
2025

Neurofibromatosis Type 1 : A General Review.

Journal of Korean Neurosurgical Society
2026

Understanding speech and language in KIF1A-associated neurological disorder.

European journal of human genetics : EJHG
2025

[Genetic analysis of a fetus pedigree affected with Thyroid dyshormonogenesis type 5 combined with familial Neurofibromatosis type 1].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2025

Loss of function of the zinc finger homeobox 4 gene, ZFHX4, underlies a neurodevelopmental disorder.

American journal of human genetics
2025

RASopathy syndromes: Understanding signaling pathway disorders leading to tumorigenesis.

Journal of the American Association of Nurse Practitioners
2025

Maternal uniparental disomy of chromosome 7: how chromosome 7-encoded imprinted genes contribute to the Silver-Russell phenotype.

Clinical epigenetics
2025

Dual Diagnosis of Sifrim-Hitz-Weiss Syndrome and Neurofibromatosis Type 1: Expanding the Phenotype of Cardiac Features in Sifrim-Hitz-Weiss Syndrome and Quick Literature Review.

American journal of medical genetics. Part A
2025

Glioblastoma in NF1: A Unique Entity-A Literature Review Focusing on Surgical Implication and Our Experience.

Current oncology (Toronto, Ont.)
2025

Generation of human induced pluripotent stem cell lines derived from a patient carrying an intragenic deletion in the NFIA gene.

Human cell
2025

A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4.

Neuro-oncology
2025

Unveiling the complexity of neurofibromatosis type 1: Innovations in genetic understanding and clinical management. A narrative review.

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
2025

Lifelong Management of Neurofibromatosis 1 Patients.

Journal of Korean Neurosurgical Society
2025

Small Intestinal Neurofibroma With Atypical 17q11.2 Microdeletions: A Rare Cause of Abdominal Distension.

JGH open : an open access journal of gastroenterology and hepatology
2025

The dose-, LET-, and gene-dependent patterns of intragenic DNA changes underlying recessive visible mutations at the autosomal gene cinnabar of Drosophila melanogaster.

Mutation research. Genetic toxicology and environmental mutagenesis
2025

From benign neurofibromas to malignant peripheral nerve sheath tumors (MPNST): a gaming among multiple factors.

Cellular oncology (Dordrecht, Netherlands)
2025

A genotype-first approach identifies high incidence of NF1 pathogenic variants with distinct disease associations.

Nature communications
2025

Analysing tumours for genetic diagnosis in mosaic neurofibromatosis type 1.

Journal of medical genetics
2025

Emerging mechanism and therapeutic potential of neurofibromatosis type 1-related nerve system tumor: Advancing insights into tumor development.

Neuro-oncology advances
2025

Moderate to Severe Short Stature and Joint Involvement in Individuals With ACAN Deletions.

Clinical endocrinology
2025

The CoREST complex is a therapeutic vulnerability in malignant peripheral nerve sheath tumors.

Scientific reports
2025

Cognition and behavior in neurofibromatosis type 1: report and perspective from the Cognition and Behavior in NF1 (CABIN) Task Force.

Genes &amp; development
2025

Intragenic deletions from whole genome sequencing of 1054 suicide deaths.

medRxiv : the preprint server for health sciences
2025

Gastric gastrointestinal stromal tumor in a patient with neurofibromatosis type I presenting with anemia: A case report.

World journal of gastrointestinal oncology
2025

Bi-allelic MED16 variants cause a MEDopathy with intellectual disability, motor delay, and craniofacial, cardiac, and limb malformations.

American journal of human genetics
2025

Exploring the Prevalence of SMN1 Duplication and Deletion in Russia and Its Impact on Carrier Screening.

International journal of molecular sciences
2025

Lysine-specific demethylase 1a is obligatory for gene regulation during kidney development.

bioRxiv : the preprint server for biology
2025

Neurofibromatosis Type 1 (NF1)-Related Ocular Signs: New Insights on Their Prevalence, Incidence, and Genotype-Phenotype Correlation in NF1 Children.

American journal of ophthalmology
2025

A rare unifocal gastric gastrointestinal stromal tumor in a young NF1 patient: A case report.

International journal of surgery case reports
2025

A Rare Coexisting Presentation of Autosomal Dominant Polycystic Kidney Disease With Rapid Deterioration of Renal Function and Neurofibromatosis Type 1.

Cureus
2025

ABCC6 gene mutational spectrum and ocular features in Mexican patients with pseudoxanthoma elasticum-related angioid streaks.

Ophthalmic genetics
2025

Clinical description and development of a prognostic score for neurofibromatosis type 1 (NF1)-associated GISTs: a retrospective study from the NETSARC.

ESMO open
2025

The nature and pathological impact of the c.1748A > G variant of the neurofibromin 1 gene.

Gene
2025

Molecular insights into genodermatoses: Genetic findings from 43 patients.

Archives of dermatological research
2025

Cancer-independent somatic mutation of the wild-type NF1 allele in normal tissues in neurofibromatosis type 1.

Nature genetics
2025

KBG syndrome: report and follow-up on three unrelated patients observed at different ages.

Italian journal of pediatrics
2025

Decade-long application of preimplantation genetic testing for DMD/BMD: analysis of five clinical strategies and embryo recombination patterns.

Human genetics
2025

Neurofibromin Deficiency Alters the Patterning and Prioritization of Motor Behaviors in a State-Dependent Manner.

The Journal of neuroscience : the official journal of the Society for Neuroscience
2025

A scarce case: Co-occurrence of neurofibromatosis type 1 and Klinefelter syndrome.

Global medical genetics
2025

Homozygous Intragenic Deletion in WDR62 in Siblings with Primary Microcephaly.

Molecular syndromology
2025

Rare Cause 5q SMA: Molecular Genetic and Clinical Analyses of Intragenic Subtle Variants in the SMN Locus.

Clinical genetics
2025

Interactions of N- and C-terminal parts of Ana1 permitting centriole duplication but not elongation.

Open biology
2025

Adeno-associated viral vector targeted evolution for neurofibromatosis gene delivery.

Trends in molecular medicine
2025

[Plastic surgical treatment of neurofibromatosis type 1].

Chirurgie (Heidelberg, Germany)
2025

Hepatoblastoma in a patient with neurofibromatosis type 1: A case report.

Cancer genetics
2025

Increased Phenotype Severity Associated with Splice-Site Variants in a Hungarian Pediatric Neurofibromatosis 1 Cohort: A Retrospective Study.

Biomedicines
2025

Allosteric modulation of NF1 GAP: Differential distributions of catalytically competent populations in loss-of-function and gain-of-function mutants.

Protein science : a publication of the Protein Society
2025

Mitochondrial Complex I Deficiency: Unraveling the Relevance of NDUFAF1 in Pediatric Hypertrophic Cardiomyopathy.

American journal of medical genetics. Part A
2024

Neurofibromatosis with diffuse intestinal ganglioneuromatosis: a case report.

Translational cancer research
2024

Jaffe-Campanacci Syndrome: A Case Report and Review of the Literature.

Cureus
2025

Multiple small bowel GIST as GI manifestation of neurofibromatosis type I: A case report.

Radiology case reports
2025

Loss of NF1 Accelerates Uveal and Intradermal Melanoma Tumorigenesis, and Oncogenic GNAQ Transforms Schwann Cells.

Cancer research communications
2024

Structural variation in nebulin and its implications on phenotype and inheritance: establishing a dominant distal phenotype caused by large deletions.

medRxiv : the preprint server for health sciences
2025

Hydroxychloroquine prevents resistance and potentiates the antitumor effect of SHP2 inhibition in NF1-associated malignant peripheral nerve sheath tumors.

Proceedings of the National Academy of Sciences of the United States of America
2025

Classification of schwannomas and the new naming convention for "neurofibromatosis-2": Genetic updates and international consensus recommendation.

The neuroradiology journal
2024

Novel Intragenic and Genomic Variants Highlight the Phenotypic Variability in HCCS-Related Disease.

Genes
2024

Irritability in Children with Rasopathies, Insights into Emotional Dysregulation and Social Skills Impairments.

Research square
2025

Standardization of Genomic Nomenclature across a Diverse Ecosystem of Stakeholders: Evolution and Challenges.

Clinical chemistry
2025

Atypical free sialic acid storage disorder associated with tissue specific mosaicism of SLC17A5.

Molecular genetics and metabolism

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Neurofibromatose tipo 1 por mutação ou deleção intragênica em NF1.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Neurofibromatose tipo 1 por mutação ou deleção intragênica em NF1

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Familial medullary thyroid carcinoma secondary to an SLC30A9 intragenic deletion and translation reinitiation.
    medRxiv : the preprint server for health sciences· 2026· PMID 41847600mais citado
  2. IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma.
    Blood· 2026· PMID 41824395mais citado
  3. Alanine-scanning mutagenesis library of MreB reveals distinct roles for regulating cell shape and viability.
    PLoS genetics· 2026· PMID 41802002mais citado
  4. Metabolic and behavioral effects of neurofibromin result from differential recruitment of MAPK and mTOR signaling.
    PLoS genetics· 2026· PMID 41785270mais citado
  5. Neurofibromin 1 (NF1) Splicing Mutation c.61-2A&gt;G: From Aberrant mRNA Processing to Therapeutic Implications In Silico.
    International journal of molecular sciences· 2026· PMID 41683605mais citado
  6. Case Report: Somatic NF2 mutation in a vestibular schwannoma arising in a patient with neurofibromatosis type 1.
    Front Oncol· 2026· PMID 41836229recente
  7. Excessive intraoperative hemorrhage during orthognathic surgery in a patient with neurofibromatosis type 1: a case report and literature review.
    Oral Maxillofac Surg· 2026· PMID 41793483recente
  8. Precision restoration of complex cervical instability and decompression for neurofibromatosis type I: a case report using patient-specific 3D-printed templates.
    Front Surg· 2026· PMID 41788354recente
  9. Isolated Anterior Mesenteric Neurofibroma: A Rare Manifestation of Neurofibromatosis Type 1.
    Cureus· 2026· PMID 41788126recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:363700(Orphanet)
  2. MONDO:0018208(MONDO)
  3. GARD:17570(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q56014112(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Neurofibromatose tipo 1 por mutação ou deleção intragênica em NF1
Compêndio · Raras BR

Neurofibromatose tipo 1 por mutação ou deleção intragênica em NF1

ORPHA:363700 · MONDO:0018208
🇧🇷 Brasil SUS
CEAF
1ASelumetinibe
Geral
CID-10
Q85.0 · Neurofibromatose (não-maligna)
Início
Infancy, Neonatal
MedGen
UMLS
C5779636
Wikidata
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades